Stocktoria
Zura Bio Ltd ZURA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-16
Zura Bio Ltd financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $42.1M | $24.4M | $44.0M | $23.7M |
| Operating income | -$75.2M | -$55.2M | -$62.6M | -$27.2M |
| Income tax | — | $0 | $0 | — |
| Net income | -$68.7M | -$52.4M | -$60.4M | -$25.7M |
| EPS (diluted) | $-1.06 | $-0.60 | $-2.09 | $-141.97 |
| Operating cash flow | -$64.8M | -$28.1M | -$15.1M | -$1.2M |
| Free cash flow | -$64.9M | -$28.2M | — | — |
| Cash & equivalents | $109.4M | $176.5M | $99.8M | $13,785 |
| Total assets | $113.9M | $179.5M | $100.8M | $5.3M |
| Total liabilities | $12.4M | $19.5M | $21.3M | $14.8M |
| Shareholders' equity | $101.5M | $148.4M | $60.9M | -$32.1M |
Source: SEC EDGAR filings · CIK 0001855644 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.